



**Compumedics Limited
Preliminary 30 June 2009 business update:**

**Strong financial gains continue – new growth platforms in place
and positioned for future sales growth**

Melbourne Australia, Tuesday 21 July, 2009

Leading medical devices company, Compumedics Limited (ASX:CMP) today announced it would post a further significant improvement in the financial performance of its businesses for the year ended 30 June 2009 when it releases its preliminary audited results later in August. Whilst these results are still subject to audit, the key points to note are:

- The Company expects to report record net profit after-tax earnings for the year ended 30 June 2009 in excess of \$2.4m.
- The Company has maintained sales for its existing core diagnostic capital equipment businesses during an incredibly difficult trading environment.
- The Company expects to report record cash generation for the financial year ended 30 June 2009.
- The Company has shipped its first SomniLink® SPAP® sleep-treatment devices to Europe.
- The Company expects to report its highest cash balances for the 30 June year-end in 4 years and has continued to reduce its bank debt, down a further 20% on a year ago to about \$2.4m.

Compumedics has maintained its core business in a very difficult economic environment whilst strengthening its financial performance and also building the future growth platforms of the business.

A key growth platform that will underpin the profitable expansion of the Company's core diagnostic business is:

- Compumedics Long-Term Monitoring (LTM) EEG device - Neuvo®, which will undergo global market rollouts over the next 12 months. This new device allows Compumedics to compete in a new global market estimated at approximately \$0.5bn pa.

While the global economy is in a state of uncertainty forward guidance will be heeded with caution at least until markets return to some level of stability.

Compumedics' growth trajectory incorporates these significant milestones.

- Tripling of revenue over 10 years to over \$37 million from \$9 million in 1999.
- Listing on the ASX in 2000 and integrating two businesses in 2002 and 2004 to develop a company with world-class product with the discipline and systems to improve profitability by at least \$7.1m post-acquisition and re-structuring.
- Establishing a unique presence covering the range of sleep markets for:
 - o diagnostics capital equipment, including conventional sleep labs and the emerging home-sleep testing, a \$1+ billion market;
 - o services for operating sleep diagnostics labs, a \$1+ billion market,
 - o treatment with the new generation SomniLink® SPAP® system a \$2+ billion market.
- Establishing brain monitoring markets for short-term EEG monitoring, and now the \$1 billion clinical long-term EEG.
- Establishing and developing market leadership in the \$1 billion ultrasound monitoring market.

Compumedics will provide further up-dates as the financial results for the year ended 30 June 2009 are finalised and audited. The Company will make additional announcements in relation to the growth platforms as material milestones are achieved.

For Further information:

Mr David Burton
Executive Chairman, CEO
Phone: + 61 3 8420 7300
Fax: +61 3 8420 7399

Mr David Lawson
Chief Financial Officer
Phone: + 61 3 8420 7300
Fax: +61 3 8420 7399

Investor Relations & Media Enquires:

Mr Rod North
Executive Director
Bourse Communications Pty Ltd
Phone: +61 3 9510 8309
Mobile: +61 (0) 408 670 706

About Compumedics

Compumedics Limited, founded in 1987, is a global leader in the design and manufacture of diagnostic technologies for sleep disorders, neurophysiology and cardiology. In 1987 Compumedics established Asia Pacific's first fully computerised sleep laboratory. Compumedics holds 80% share of the Australian sleep-diagnostic market, and has a major and rapidly growing presence in the US, European and Asian marketplaces for its sleep, neurological, and Doppler blood-flow diagnostic monitoring devices. **In 1995** the company was selected to supply equipment to the US Sleep Heart Health Study, the world's largest sleep study of its kind, currently exceeding 14,000 studies with 20,000 patients scheduled by 2008. With headquarters in Melbourne, Australia and offices in the United States, and Europe the products are distributed in over 50 countries. **In 1998** Compumedics was awarded the overall Australian Exporter of the Year. **In 2000** Compumedics was listed on the Australian Stock Exchange. **In 2002**, Compumedics acquired US-based Neuroscan - the world's leading supplier of instruments for brain-research. In the US - the world's largest medical device market - Neuroscan holds around 90% of the market for brain-research products. **In 2003** Compumedics was awarded the Frost & Sullivan Award for Market Expansion Strategy. **In 2004**, Compumedics acquired German-based DWL Elektronische GmbH, enabling Compumedics to expand its global operations into the neurovascular and cardio-vascular diagnostic fields. **In 2006**, Compumedics was awarded the Frost and Sullivan Technology Leadership award for the innovative Somté recorder product. **In 2007**, Compumedics and Chairman were inducted into the Victorian Manufacturing Hall of Fame. **In 2008** the DWL division received the top 100 German Innovation award. With 20,000 systems installed globally across the finest hospital, universities and clinics the Compumedics sales have grown more than 4 fold from \$9 million (1999) to \$39 million (2008). **In 2009** Compumedics received an award for design excellence for its new generation Grael™ sleep diagnostic system.
www.compumedics.com